美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · MNKD近 30 天 3 則 · 第 1 / 1 頁
- MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
- MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
- FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
- MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
- MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
- Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
- MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
- MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
- MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
- FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
- How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix Autoinjector
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。